Statte

• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
• ROMANCE Recruiting
  2025-521319-38-00 4 2026-03-11 metastatic colorectal cancer
• A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting
  2024-514500-14-00 5 2025-12-15 Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
• A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting
  2024-517553-26-00 5 2025-11-12 Advanced ALK-positive non-small cell lung cancer (NSCLC)
• A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting
  2025-520473-40-00 4 2025-09-29 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
• CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met … Recruiting
  2024-519322-20-00 5 2025-07-21 metastatic colorectal cancer
• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 Recurrent ovarian cancer
• A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type … Recruiting
  2024-519481-44-00 4 2025-01-08 colorectal metastatic cancer
• PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION Recruiting
  2024-519286-21-00 5 2024-12-17 MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA … Recruiting
  2024-518534-81-00 4 2021-07-01 metastatic colorectal cancer
• NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta … Recruiting
  2024-519007-10-00 10 2020-10-22 Locally advanced stage II/III rectal cancer
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm … Recruiting
  2024-517200-10-00 4 2020-01-31 Advanced non-small-cell lung cancer
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503572-24-00 5 2022-03-02 Chronic Obstructive Pulmonary Disease (COPD)
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)

Showing 1–23 of 23 trials